Aberdeen Investments
VC Fund
Scotland, United States
Aberdeen Investments is a VC fund in Scotland focused on Medical and Health Care. Aberdeen Investments is focused on expanding our direct and advised wealth platforms, as well as repositioning our professional asset management business to suit client demand.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Aberdeen Investments invests in
Stages Aberdeen Investments invests in
Countries Aberdeen Investments invests in
Investment Focus
Industry
- Medical 3 (43%)
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Life Science 2 (29%)
- Therapeutics 2 (29%)
Stage
- Post-IPO Equity 3 (43%)
- Series A 1 (14%)
- Post-IPO Debt 1 (14%)
- Corporate Round 1 (14%)
Country
- United States 4 (57%)
- Spain 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ACCIONA
|
ACCIONA is one of the foremost Spanish business corporations, leader in the development and management of infrastructure, renewable energy, water and services. Listed on the selective Ibex-35 stock exchange index, it is a benchmark for the market. The Company was set up over a century ago and is made up of more than 30,000 employees and has apresence in more than 30 countries on five continents. See more at: http://www.acciona.com | Post-IPO Debt / Jul 31, 2026 | |
|
Velian
|
Velian is a European e-mobility infrastructure provider that designs, builds, and operates EV charging networks for public, logistics, and real estate clients. It designs, finances, builds, and operates EV charging infrastructure. | Corporate Round / May 18, 2026 | |
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $400M / Post-IPO Equity / Feb 13, 2026 | |
Third Arc Bio
|
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M / Series A / Feb 04, 2026 | |
Precision BioSciences
|
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $75M / Post-IPO Equity / Nov 10, 2025 | |
Jade Biosciences
|
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $135M / Post-IPO Equity / Oct 07, 2025 | |
|
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $5.1M / Post-IPO Equity / Apr 09, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Aberdeen Investments invest in?
Aberdeen Investments invests primarily in Medical, Health Care and Biotechnology startups, most often at Post-IPO Equity and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Aberdeen Investments last invest?
The most recent investment recorded for Aberdeen Investments closed in Jul 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
